Email
Print
In - Vivo Contract Research Organisation Market - Forecast(2024 - 2030)
In - Vivo Contract Research Organisation Market Overview
In - Vivo Contract Research Organisation Market
Size is estimated to reach $6.1 billion by 2027. Furthermore, it is poised to
grow at a CAGR of 7.9% over the forecast period of 2022-2027. CRO stands for Contract
Research Organisation, and it is a company that provides contract research
services to biotechnology, pharmaceutical, and medical devices firms. Biologic
assay development, Clinical research, biopharmaceutical development, clinical trial
management, preclinical research, pharmacovigilance, and commercialization are
only some of the services offered by CROs. Preclinical testing for drug
development and disease pathology is referred to as In Vivo CRO. The market for
contract research organizations is growing in Vivo as pharma firms extend their
pipeline products for Drug discovery and produce new molecules in order to stay
profitable and patentable in the market. CROs are required by drug
manufacturers to gather and investigate adequate data in order to create new
drugs, which is one of the main reasons for the rising need for CROs in the
pharmaceutical drug development market. The usage of Contract Research
Organization services allows firms to focus entirely on their own manufacturing
capacity as well as improving and developing their internal processes.
The rising number of patients and diseases like Cancer, Pain
management diseases and the shifting preference of pharmaceutical industries
toward outsourcing clinical and preclinical trials to focus on their core
business are some
of the factors driving the In - Vivo Contract Research Organisation Market
growth during the forecast period 2022-2027.
In - Vivo Contract Research Organisation Market Report Coverage
The
report: “In - Vivo Contract Research Organisation Market Forecast
(2022-2027)", by Industry ARC covers an in-depth analysis of the
following segments of the In - Vivo Contract Research Organisation Market.
By
Animal Type – Rodent (Mice, Rats), and Non-rodent (Hamsters,
guinea pigs).
By
Indication- Oncology (Lymphoma, Leukemia, Soft tissue cancer),
Autoimmune disorder (Rheumatoid arthritis, Myasthenia gravis, Ulcerative
Colitis, Psoriasis), CNS (Alzheimer’s, Epilepsy, Parkinson’s), Pain management
(Neuropathic pain, Fibromyalgia), Obesity, Diabetes (Type-1 and Type-2),
Others.
By
End-Users- Hospitals, Specialty Clinics, Others.
By
Geography- North America (U.S., Canada, Mexico), Europe
(Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of
Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New
Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest
of South America), and Rest of the World (the Middle East, and Africa).
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021 on account of the progress of technology for in-vivo CROs in this region has resulted in an increase in the number of clinical trials owing to an increase in patients and disease prevalence. Asia-Pacific is estimated to offer lucrative growth opportunities to the manufacturers owing to the increasing prevalence of chronic diseases like Rheumatoid and Osteoarthritis., the demand for better healthcare facilities. The proliferation of cancer is predicted to augment the market growth during the forecast period of 2022-2027.
- The growing prevalence of cancer and other CNS disorders is estimated to drive the market growth of In - the Vivo Contract Research Organisation Market. Owing to expensive clinical trials In - Vivo Contract Research Organisation Market poses threat to Market growth.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the In - Vivo Contract Research Organisation Market Report.
In - Vivo Contract Research Organisation Market: Market Share (%) by region, 2021
For more details on this report - Request for Sample
In - Vivo Contract Research Organisation Market Segmentation Analysis- By Animal Type
Based on the product can be further segmented into Rodent and Non-rodent.
Rodent held a dominant market share in the year 2021 and is estimated to be the
fastest-growing, with a CAGR of 8.5% over the forecast period of 2022-2027 owing
to the similarity of rodents with humans. Rodents are commonly used in experiments
since they're so similar to humans. Rats and humans share 90% of their DNA,
according to the Koshland Science Museum. So, they are the most effective
method for determining the nature of various gene interactions in people.
According
to NCBI, 2019, live animal research is crucial for scientists to understand how
diseases arise and spread throughout the body, as well as to identify new and
more effective techniques to detect and treat these diseases. Although animal
studies (nearly 95 percent of which are conducted in mice) are vital for
acquiring a better knowledge of complicated disease processes, they
need only be used when other techniques, such as disease cell lines, have
been exhausted. Regulatory agencies also demand animal research before any
trials of novel medications can be conducted in humans. Preclinical animal
research is, in fact, necessary for toxicological evaluations and human
medication licensing. In order to reduce negative consequences, humane concerns
are highlighted. Hence, rodents dominate the market of In - Vivo Contract
Research Organisation.
In - Vivo Contract Research Organisation Market Segmentation Analysis- By Indication
In
- Vivo Contract Research Organisation Market based on the Indication can be
further segmented into Oncology, Autoimmune, CNS, Pain management, Obesity,
Diabetes, Others. Oncology held a dominant market share in the year 2021 and is
estimated to be the fastest-growing, with a CAGR of 8.7% over the forecast
period of 2022-2027 as the number of cancer patients grows, numerous medication
research and clinical trials are conducted in oncology. According to National
Cancer Institute, in 2021, Cancer is a disease in which some of the body’s
cells grow uncontrollably and spread to other parts of the body. According to
World Health Organization 2022, Cancer is the biggest cause of mortality
globally, with approximately 10 million fatalities estimated in 2020,
accounting for roughly one in every six deaths. Breast, lung, colon, rectum,
and prostate cancers are the most frequent malignancies.
According
to FDA 2022, Preclinical investigations are usually not particularly large.
These studies, on the other hand, need to offer thorough information on the dose and degrees of toxicity of anticancer drugs. Researchers analyze their
findings after preclinical testing and decide if the medicine indeed be studied
in humans.
In - Vivo Contract Research Organisation Market Segmentation Analysis- By Geography
The
In - Vivo Contract Research Organisation Market based on Geography can be
further segmented into North America, Europe, Asia-Pacific, South America, and
the Rest of the World. North America held a dominant market share of 35% in the
year 2021 as compared to its other counterparts on account of increasing
healthcare spending and the number of cancer patients growing, numerous
medication research and clinical trials are conducted in oncology. According to
the National Clinical Studies Registry (NCT), in 2020 there are 11,865
active clinical trials in various stages for cancer indications in the United
States.
However,
Asia-Pacific is estimated to be the fastest-growing over
the forecast period of 2022-2027 on account of economic development and a large
patient base affecting the expansion of the healthcare business in this region.
In - Vivo Contract Research Organisation Market Drivers
Rising Prevalence of Chronic Diseases mainly Cancer is Driving the Market of In - Vivo Contract Research Organisation
Cancer
is one of the life-threatening diseases which is more prevalent mainly owing to
lifestyle changes. Globally, drugs that help in the treatment of cancer are in
high demand. According to WHO, 2018, Cancer is one of the biggest causes of
mortality. Nearly half of all cancer deaths 46% in 2017 are persons aged 70 or
older. The worldwide number of cancer fatalities is rising as the world's
population grows and ages. According to American Cancer Association 2022, with estimated
numbers of new cancer cases and deaths in 2022, there will be an estimated 1.9
million new cancer cases diagnosed and 609,360 cancer deaths in the United
States, thereby, driving the market growth.
According
to Stanford Children's Health, in 2020, every year, around 3.5 million children
aged 14 and under are injured as a result of sports. Knee injuries accounted
for almost 9% of the total number of injuries. In addition, with children's
increased interest in sports activities, there has been a five-fold increase in
ACL injuries in recent years. Hence, the rising prevalence of chronic diseases is
one of the key driving factors for the market.
Rising Number of Clinical Trials Is Driving Market Growth
Clinical
trials are rising as the number of patients and diseases is increasing
continuously. According to the National Clinical Studies (NCT) Registry, there
are about 38,445, 5,692, and 726 clinical trials relating to cancer in
different stages of research in the United States, Canada, and Mexico as of
2021. According to WHO 2020, the number of newly recruited trials registered on
ICTRP for most WHO areas increased steadily during the analyzed period.
Hence, a rising number of clinical trials is propelling the market.
In - Vivo Contract Research Organisation
Market Challenges
The huge cost of Clinical trials is a Challenge for
the Market
The
experiment is more costly if additional patients are required. As a result, the
cost varies significantly depending on the stage: 5-50 patients for a phase I
study, 50-300 people for a phase II trial, and 300-3000 individuals for a phase
III trial. In recent years, the cost of enrolling a single patient has also
increased. As the number of clinical studies done throughout the world
increases, so does the rivalry for patients.
The
number of patients required is influenced by more than just the study stage.
This component is highly influenced by the design of clinical trials and the
illness indication. Typically, a novel medicine for an orphan illness with no
other authorized therapies can recruit between 10 and 50 patients in a clinical
trial. In a cardiovascular or central nervous system (CNS) illness
study, on the other hand, when the new medicine is only given marginal improvements
over existing drugs, hundreds or even thousands of patients are included in a
placebo or active-controlled trial to assure statistical power. Hence, the Huge
cost of Clinical trials is a Challenge for the Market.
In - Vivo Contract Research Organisation Industry Outlook
Product
launches, mergers and acquisitions, joint ventures, and geographical expansions
are key strategies adopted by players in the In - Vivo Contract Research
Organisation Market. The top 10 In - Vivo Contract Research Organisation Market
companies are-
- American Preclinical Services, LLC.
- BTS Research, Charles River
Laboratories International, Inc.
- Chiltern International Ltd., Covance
Inc.
- ICON Plc.
- INC Research inVentiv Health
- PAREXEL International Corporation
- Pharmaceutical Product Development,
LLC.
- IQVIA
- EVERSANA
- WuXi
AppTec, Inc.
Recent developments
- In February 2022, THREAD, leading technology and global provider enabling electronic clinical outcome assessments (eCOAs) and decentralised clinical trials (DCTs), and EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, today announced a new combined offering to give pharmaceutical companies a comprehensive and simultaneous view of clinical research participants, followed by data and detailed analysis across the care continuum.
- In February 2020, the life sciences company IQVIA is a prominent global provider of advanced analytics, technological solutions, and contract research services, announced the introduction of Avacare Clinical Research NetworkTM, a technology-based global site network that expands clinical trial possibilities at established clinical and research sites. Avacare's exclusive analytical technologies assist sites in the Avacare network in better matching patients to clinical trials.
- In May 2019, ICON plc, a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology, and medical device industries, announced that it has purchased a majority stake in MeDiNova Research, a site network with research sites in key European and African markets.
Relevant Titles
Report Code: HCR 0176
Report Code: HCR 0004
Report Code: HCR 0644
1. In - Vivo Contract Research Organisation Market - Overview
1.1 Definitions and Scope
2. In - Vivo Contract Research Organisation Market - Executive Summary
3. In - Vivo Contract Research Organisation Market - Comparative Analysis
3.1 Company Benchmarking - Key Companies
3.2 Global Financial Analysis Key Companies
3.3 Market Share Analysis Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. In - Vivo Contract Research Organisation Market - Startup Companies Scenario Premium
4.1 Key Startup Company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Venture Capital and Funding Scenario
5. In - Vivo Contract Research Organisation Market – Industry Market Entry Scenario Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing Business Index
5.3 Case Studies of Successful Ventures
6. In - Vivo Contract Research Organisation Market - Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters Five Force Model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. In - Vivo Contract Research Organisation Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. In - Vivo Contract Research Organisation Market – By Type of animal
8.1 Rodent
8.1.1 Mice
8.1.2 Rat
8.1.3 Others
8.2 Non-rodent
8.2.1 Hamsters
8.2.2 Guinea pigs
8.2.3 Others
9. In - Vivo Contract Research Organisation Market – By Indication
9.1 Oncology
9.1.1 Lymphoma
9.1.1.1 Hodgkin’s Lymphoma
9.1.1.2 Non-Hodgkin’s lymphoma
9.1.2 Leukemia
9.1.2.1 Acute
9.1.2.2 Chronic
9.1.3 Soft tissue cancer
9.1.3.1 Muscle
9.1.3.2 Blood vessel
9.1.3.3 Fat
9.1.3.4 Fibrous tissue
9.1.3.5 Nerves
9.2 Autoimmune
9.2.1 Rheumatoid Arthritis
9.2.2 Myasthenia Gravis
9.2.3 Psoriasis
9.2.4 Ulcerative colitis
9.3 CNS
9.3.1 Amyloid lateral sclerosis
9.3.2 Epilepsy
9.3.3 Alzheimer’s
9.3.4 Parkinson’s
9.3.5 Psychosis
9.4 Pain management
9.4.1 Neuropathic pain
9.4.2 Fibromyalgia
9.5 Obesity
9.6 Diabetes
9.6.1 Type-1
9.6.2 Type-2
9.7 Others
10. In - Vivo Contract Research Organisation Market – By End User
10.1 Hospitals
10.2 Specialty Clinics
10.3 Others
11. In - Vivo Contract Research Organisation Market - By Geography
11.1 North America
11.1.1 U.S.
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 U.K.
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 India
11.3.3 Japan
11.3.4 South Korea
11.3.5 Australia & New Zealand
11.3.6 Rest of Asia-Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Chile
11.4.4 Colombia
11.4.5 Rest of South America
11.5 Rest of the World
11.5.1 Middle East
11.5.2 Africa
12. In - Vivo Contract Research Organisation Market - Entropy
13. In - Vivo Contract Research Organisation Market – Industry/Segment Competition Landscape Premium
13.1 Market Share Analysis
13.1.1 Global Market Share – Key Companies
13.1.2 Market Share by Region – Key companies
13.1.3 Market Share by Countries – Key Companies
13.2 Competition Matrix
13.3 Best Practices for Companies
14. In - Vivo Contract Research Organisation Market – Key Company List by Country Premium Premium
15. In - Vivo Contract Research Organisation Market - Company Analysis
15.1 Company 1
15.2 Company 2
15.3 Company 3
15.4 Company 4
15.5 Company 5
15.6 Company 6
15.7 Company 7
15.8 Company 8
15.9 Company 9
15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.